Metformin Use Review in Non-Alcoholic Fatty Liver Disease (NFLDA) and Students Survey

Download PDF

This study presented the literature review findings and the knowledge and opinions of 41 first-year pharmacy students regarding metformin's role in managing non-alcoholic fatty liver disease (NAFLD), achieving a 92% response rate. NAFLD, affecting about a quarter of the global population, is linked with obesity, high cholesterol, and diabetes, presenting a substantial public health issue. Metformin, known for treating type 2 diabetes, is considered for NAFLD management due to its potential in improving insulin sensitivity and reducing hepatic gluconeogenesis. Survey results, analyzed using SPSS software, showed varied perceptions across demographics. Younger participants (18-24) were more familiar with metformin than older counterparts. Females were more inclined towards recommending metformin for NAFLD, understanding its benefits better than males. Notably, employed individuals and those residing outside certain states demonstrated greater awareness of metformin, suggesting regional knowledge disparities. Participants with a 4-year degree displayed enhanced familiarity with metformin's application in NAFLD. The findings highlight the need for targeted educational efforts to bridge knowledge gaps about metformin and NAFLD management among pharmacy students. This knowledge is crucial for informing curriculum enhancements and integrating NAFLD management into therapeutic courses or modules for aspiring healthcare professionals. Significant associations were identified between students' age, gender, employment status, residency, income level, and their understanding of metformin, indicating diverse educational needs.